Huge Sales Quarter Positions Gilead To Be Significant M&A Player
This article was originally published in The Pink Sheet Daily
Executive Summary
Hepatitis C franchise adds nearly $3 billion to Gilead’s cash coffers, leaving the firm to ponder bigger ambitions.
You may also be interested in...
Milligan’s Retirement Means New CEO For New Gilead
While Milligan’s year-end departure topped the news, Gilead posted solid sales growth for Yescarta, got the HIV franchise back to growth and saw HCV’s decline largely stabilize. CSO McHutchison, meanwhile, predicted that selonsertib could be first to market in NASH.
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Sharply declining HCV sales, three upcoming patent expirations and a lack of near-term pipeline prospects other than HIV candidate bictegravir leave the specialty firm needing to spend some of its gigantic cash reserves on assets to revitalize its portfolio and/or stimulate the R&D engine.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.